k
keynews.ai
keynews.ai
WorkThe story, in brief

Why AI can transform pharma — but nature cannot be hurried

AI can compress drug discovery timelines. But the FDA still won't.

Reporting by Financial Times Technology 1 min brief
Illustration of two anonymous hands arranging task cards around an amber tool on a shared desk.
People, judgement and the changing nature of work.AI illustration by KeyNews
The KeyNews take

Why it matters

While AI accelerates the science of pharma R&D, regulatory and biological realities mean time-to-market gains are capped—a critical reality check for investors betting on moonshot biotech timelines.

The key facts

7 to know

  1. Article explores AI's potential to transform pharmaceutical development

  2. Emphasizes tension between AI speed and regulatory/biological constraints

  3. Published in Financial Times (credible source)

  4. Focus on strategic implications for pharma industry rather than specific AI model capability or deal

  5. AI's potential to transform drug development pipeline

  6. Regulatory/approval timelines not accelerating with AI capability gains

  7. Biological development cycles constrain time-to-market despite computational speed

Go to the source

Financial Times Technologyft.com

Publisher excerpt: Artificial intelligence has the potential to fundamentally change the development of new treatments
Read original report
Back to today's editionMore work news

The wider picture

View all
Illustration of independent geometric mechanisms passing paper tasks along branching amber tracks.
AI illustration by KeyNews
Work01

The Emerging M&A Map For AI Agent Security

As agents move from pilots to production with real system access, enterprise security models are breaking. The M&A map is forming around who controls agent permissions, monitoring, and governance — a new class of identity management problem that practitioners need to architect for now.

Crunchbase News
Illustration of two anonymous hands arranging task cards around an amber tool on a shared desk.
AI illustration by KeyNews
Work02

AI privacy budgets: Ask for the calculation, not the claim

Enterprise AI buyers are accepting privacy budget numbers without verification. This deep dive explains what questions to ask vendors about federated learning privacy claims, and why the gap between contractual promises and operational evidence is where real exposure lives.

CIO
Illustration of two anonymous hands arranging task cards around an amber tool on a shared desk.
AI illustration by KeyNews
Work03

Andrew Kelley Interview: Why He Built Zig, Banned AI Contributions, and Moved Zig off GitHub

Open-source governance is shifting in response to AI-generated contributions. Zig's formal ban and migration off GitHub signals broader industry concern about code quality, maintainer burden, and the cultural impact of automated submissions — a flashpoint for how AI changes the work of software development.

InfoQ AI/ML